Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm has been embroiled in controversy for a while. Now, there are reports that the drug could have some potentially serious safety issues. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Biogen's blockbuster hopes for Aduhelm could be doomed.

Continue reading

Source Fool.com